SuperworthExelixis market cap EXEL
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $16B
- Highest close in our data
- $16B
- Oct 2026
Exelixis is worth $16B at the close on Oct 23, 2026, at $64.53 a share.
That is up 53% over the last year and up 136% over five years.
Its highest close in our data was $16B in Oct 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $16B | $10.7B | $16B | +29% |
| 2025 | $12.4B | $9.2B | $12.6B | +28% |
| 2024 | $9.7B | $6B | $10.4B | +29% |
| 2023 | $7.5B | $5.3B | $7.5B | +44% |
| 2022 | $5.2B | $5B | $7.4B | −11% |
| 2021 | $5.8B | $5B | $8B | −7% |
| 2020 | $6.2B | $4.6B | $8.3B | +13% |
| 2019 | $5.5B | $4.8B | $7.4B | −5% |
| 2018 | $5.8B | $4.3B | $9.4B | −35% |
| 2017 | $9B | $4.4B | $9B | +111% |
| 2016 | $4.3B | $874.8M | $5B | +233% |
| 2015 | $1.3B | $318.2M | $1.5B | +394% |
| 2014 | $259.6M | $259.6M | $1.5B | −76% |
| 2013 | $1.1B | $810.2M | $1.1B | +32% |
| 2012 | $828M | $621.2M | $967.6M | +35% |
| 2011 | $614.1M | $512.3M | $985.6M | n/a |
Against its peers
Companies in Biotechnology nearest Exelixis' size, closest first, today.
| Company | Market cap |
|---|---|
| EXELExelixis | $16B |
| NBIXNeurocrine Biosciences | $14.5B |
| HALOHalozyme Therapeutics | $14.3B |
| TECHBIO-TECHNE | $11.4B |
| INCYIncyte | $23.5B |
| UTHRUnited Therapeutics | $25.2B |
| RGENRepligen | $10B |
| KRYSKrystal Biotech | $9.2B |
| ALNYAlnylam Pharmaceuticals | $30B |
| ONCBeOne Medicines | $42.9B |
| REGNRegeneron Pharmaceuticals | $82.9B |
| Peer median | $19B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Exelixis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.